576 related articles for article (PubMed ID: 31611300)
1. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
Liang C; Shi S; Qin Y; Meng Q; Hua J; Hu Q; Ji S; Zhang B; Xu J; Yu XJ
Gut; 2020 May; 69(5):888-900. PubMed ID: 31611300
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1.
Jiang Y; He R; Jiang Y; Liu D; Tao L; Yang M; Lin C; Shen Y; Fu X; Yang J; Li J; Huo Y; Hua R; Liu W; Zhang J; Shen B; Zhang Z; Sun Y
Cell Death Dis; 2019 Dec; 10(12):948. PubMed ID: 31827081
[TBL] [Abstract][Full Text] [Related]
3. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
[TBL] [Abstract][Full Text] [Related]
6. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients.
Paiella S; Malleo G; Cataldo I; Gasparini C; De Pastena M; De Marchi G; Marchegiani G; Rusev B; Scarpa A; Girelli R; Giardino A; Frigerio I; D'Onofrio M; Secchettin E; Bassi C; Salvia R
Langenbecks Arch Surg; 2018 Mar; 403(2):213-220. PubMed ID: 28983662
[TBL] [Abstract][Full Text] [Related]
7. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome.
Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
[TBL] [Abstract][Full Text] [Related]
8. SMAD4 Y353C promotes the progression of PDAC.
Wang Z; Li Y; Zhan S; Zhang L; Zhang S; Tang Q; Li M; Tan Z; Liu S; Xing X
BMC Cancer; 2019 Nov; 19(1):1037. PubMed ID: 31684910
[TBL] [Abstract][Full Text] [Related]
9. SNHG17 alters anaerobic glycolysis by resetting phosphorylation modification of PGK1 to foster pro-tumor macrophage formation in pancreatic ductal adenocarcinoma.
Lin J; Liu Y; Liu P; Qi W; Liu J; He X; Liu Q; Liu Z; Yin J; Lin J; Bao H; Lin J
J Exp Clin Cancer Res; 2023 Dec; 42(1):339. PubMed ID: 38098044
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
11. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.
Liang C; Xu J; Meng Q; Zhang B; Liu J; Hua J; Zhang Y; Shi S; Yu X
Autophagy; 2020 Mar; 16(3):486-500. PubMed ID: 31177911
[TBL] [Abstract][Full Text] [Related]
12. Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis.
Leung L; Radulovich N; Zhu CQ; Wang D; To C; Ibrahimov E; Tsao MS
PLoS One; 2013; 8(12):e84366. PubMed ID: 24386371
[TBL] [Abstract][Full Text] [Related]
13. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
14. SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization.
Dai C; Rennhack JP; Arnoff TE; Thaker M; Younger ST; Doench JG; Huang AY; Yang A; Aguirre AJ; Wang B; Mun E; O'Connell JT; Huang Y; Labella K; Talamas JA; Li J; Ilic N; Hwang J; Hong AL; Giacomelli AO; Gjoerup O; Root DE; Hahn WC
Cell Rep; 2021 Jul; 36(4):109443. PubMed ID: 34320363
[TBL] [Abstract][Full Text] [Related]
15. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
16. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.
Wang JD; Jin K; Chen XY; Lv JQ; Ji KW
Oncotarget; 2017 Mar; 8(10):16704-16711. PubMed ID: 28053288
[TBL] [Abstract][Full Text] [Related]
18. Clinical Effect of Driver Mutations of
Gu Y; Ji Y; Jiang H; Qiu G
Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
[No Abstract] [Full Text] [Related]
19. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
20. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
